Building successful life sciences companies.

With over $200 million of committed capital under management, Genesys is one of the largest Canadian-based exclusively focused on the life sciences industry. View our portfolio.

Building companies, accelerating development.

Genesys Capital is focused on building companies in the high-growth sectors of healthcare and biotechnology. Through its expertise and network, Genesys accelerates the development of commercially viable emerging companies that represent promising life science investment opportunities.

Investor Login

Sign in to our secure investor area to receive personalized updates and information. Login now »

Recent Additions

Fusion Pharma Announces First Patient Dosing In A Phase 1 Clinical Trial Of [225Ac]-FPI-1434 Injection In Patients With Advanced Solid Tumors
February 19, 2019 – Today Fusion Pharmaceuticals announced that the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors... Read more
Inversago Pharma receives $7 million in series A financing
25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue its development plan and advance its CB1 platform.... Read more